X4 Pharmaceuticals, Inc. Stock
X4 Pharmaceuticals, Inc. Stock
Currently there is a rather positive sentiment for X4 Pharmaceuticals, Inc. with 5 Buy predictions and 1 Sell predictions.
With a target price of 9 € there is potential for a 5273.13% increase which would mean more than doubling the current price of 0.17 € for X4 Pharmaceuticals, Inc..
So far the community has only identified positive things for X4 Pharmaceuticals, Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of X4 Pharmaceuticals, Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of X4 Pharmaceuticals, Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc. | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | 5.840% | -31.089% | -20.320% | -73.274% | -73.178% | -79.946% | -96.948% |
| Evolus Inc | -0.060% | 35.230% | 25.286% | 50.500% | 32.550% | -18.831% | -21.049% |
| Rhythm Pharmaceuticals | 0.000% | 1.047% | 1.579% | 21.384% | 3.209% | 295.492% | 710.924% |
Comments
X4 Pharmaceuticals (XFOR) was upgraded by Wells Fargo & Company to "strong-buy".
Show more
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals (XFOR) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $11.00 price target on the stock.
Show more
Ratings data for XFOR provided by MarketBeat
X4 Pharmaceuticals (XFOR) is now covered by Leerink Partners. They set an "outperform" rating and a $12.00 price target on the stock.
Show more
Ratings data for XFOR provided by MarketBeat